Featuring an interview with Dr Gilles Salles, including the following topics:
- Biology underlying B-cell lymphomas, role of Bruton tyrosine kinase (BTK) inhibitors in lymphomas and reason for cure in diffuse large B-cell lymphoma (DLBCL) versus indolent lymphomas (0:00)
- Efficacy, tolerability and optimal sequencing of selinexor, polatuzumab vedotin/bendamustine/rituximab, tafasitamab/lenalidomide and loncastuximab tesirine for DLBCL (6:32)
- Ongoing trials evaluating selinexor, tafasitamab/lenalidomide and loncastuximab tesirine for DLBCL (14:24)
- Managing cytokine release syndrome associated with bispecific antibodies; eligibility considerations with bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy (18:02)
- Case: A man in his late 60s diagnosed with DLBCL who has a history of ulcerative colitis and mitral valve repair (28:17)
- Case: A woman in her early 80s with transformed DLBCL (35:14)
- Case: A woman in her early 40s with DLBCL unresponsive to CAR T-cell therapy (38:05)
CME information and select publications
Research To Practice | Oncology Videos